1.Pula JH, er al. Longitudinally extensive optic neuritis in neuromyelitis optica spectrum disorder. J Neurol Sci. 2014 Oct 15;345(1-2):209-12.
2.Portaccio E, et al. Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Mult Scler. 2022 Mar;28(3):472-479.
3.Kahila S, et al. Brain MRI activity during the year before pregnancy can predict long-term clinical worsening in patients with Multiple Sclerosis. Neurol Sci. 2023 Nov;44(11):3989-3996.
4.Kristen Krysko, et al. C174 presentation at American Academy of Neurology Annual Meeting, Denver, CO, USA; April 13-18, 2024
5.Dalia L Rotstein, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015 Feb;72(2):152-8.
6.Hauser SL, et al. Effect of ofatumumab on NEDA-3: analysis from the pooled Phase 3 ASCLEPIOS I and II trials. Poster presented at EAN 2020. LB62
7.Hauser SL, et al. Presented at ECTRIMS 2019. OP336.
8.Valor L, et al. Treatment with monoclonal antibodies and pregnancy in women with systemic inflammatory diseases: A special situation. Reumatol Clin. 2016 Nov-Dec;12(6):359-360.
9.KESIMPTA. Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2020.
10.Sandra Vukusic, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004 Jun;127(Pt 6):1353-60.
11.Maria Houtchens, et al. Neurol Neuroimmunol Neuroinflamm. 2020 Sep 11;7(6):e890.
12.Ruggieri et al. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Multiple Sclerosis and Demyelinating Disorders (2018)
13.Cerqueira JJ, et al. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850.
14.中华医学会神经病学分会神经免疫学组. 多发性硬化诊断与治疗中国指南（2023版）[J]. 中华神经科杂志,2024,57(01)：10-23.
15.Heinz Wiendl,et al. ePresentation at the annual meeting of the European Academy of Neurology, 2020
16.Ludwig Kappos,et al. Five-Year Efficacy Outcomes of Ofatumumab in Relapsing MS Patients: Insights From ALITHIOS Open-label Extension Study. EPR-097. Poster Presentation at European Academy of Neurology (EAN), 2023.
17.Hauser SL, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557.
18.Data on file. OMB157G (ofatumumab) OMB157G 5.3.5.3. Statistical overview. Novartis Pharmaceuticals Corp; East Hanover, NJ. December 2019.
19.Jeffrey A. Cohen, et al. Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis. AAN 2023. P8.004.
